Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)
• Dolutegravir + Emtricitabine/Tenofovir Alafenamide (dolutegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-06-06